A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin&reg;), a botulinum neurotoxin type A free from complexing proteins

A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin&reg;), a botulinum neurotoxin type A free from complexing proteins

Joohi Jimenez-ShahedDepartment of Neurology, Baylor College of Medicine, Houston, TX, USAAbstract: Dystonia is a movement disorder of uncertain pathogenesis that is characterized by involuntary and inappropriate muscle contractions which cause sustained abnormal postures and movements of multiple or...

Full description

Bibliographic Details
Main Author:	Jimenez-Shahed J
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-12-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/a-new-treatment-for-focal-dystonias-incobotulinumtoxina-xeominreg-a-bo-a8944

Similar Items

Profile of Xeomin&reg; (incobotulinumtoxinA) for the treatment of blepharospasm
by: Park J, et al.
Published: (2011-06-01)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
by: Harald Hefter, et al.
Published: (2021-02-01)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
by: Francesca Morgante, et al.
Published: (2019-11-01)

AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients
by: Malgorzata Field, et al.
Published: (2018-12-01)

Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin versus Toxin-Naïve Subjects with Cervical Dystonia
by: Hubert Fernandez, et al.
Published: (2013-05-01)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
by: Antonio Galván Ruiz, et al.
Published: (2019-01-01)

Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine
by: Ioana Ion, et al.
Published: (2018-06-01)

Pharmacoeconomic analysis of Xeomine® for treatment patients with focal dystonia
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients
by: Malgorzata Field, et al.
Published: (2019-02-01)

Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series
by: Denys, P., et al.
Published: (2022)

Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia
by: Hubert Fernandez, et al.
Published: (2013-05-01)

Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
by: Ruth Kent, et al.
Published: (2021-07-01)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
by: Yutskovskaya Y, et al.
Published: (2015-06-01)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
by: Santamato A
Published: (2016-01-01)

Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm
by: Hubert H. Fernandez, et al.
Published: (2014-07-01)

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
by: Jost WH, et al.
Published: (2015-04-01)

Pharmacoeconomic analysis of flexible-dose administration regimen of Xeomine® in patients with focal dystonia
by: A. E. Cheberda, et al.
Published: (2018-06-01)

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
by: Klemens Fheodoroff, et al.
Published: (2020-03-01)

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
by: Prager W
Published: (2013-03-01)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
by: Koji Makino, et al.
Published: (2020-03-01)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
by: de Sanctis Pecora C
Published: (2020-02-01)

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
by: Nikolis A, et al.
Published: (2018-07-01)

Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait
by: Maurizio Falso, et al.
Published: (2012-05-01)

Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA
by: Jörg Wissel, et al.

“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
by: Giancarlo Ianieri, et al.
Published: (2018-03-01)

Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis
by: Petr Kaňovský, et al.
Published: (2021-01-01)

IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study
by: Pavicic T, et al.
Published: (2015-03-01)

IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability
by: Angel León-Valenzuela, et al.
Published: (2020-04-01)

Botulinum Neurotoxin Typ A (Xeomin®) als Therapieoption der allergischen und intrinsischen Rhinitis: Eine randomisierte, doppelblinde, Placebo-kontrollierte Studie
by: Winterhoff, Jan
Published: (2015)

Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats
by: Feng Y, et al.
Published: (2017-06-01)

Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns
by: Fariborz Rahimi, et al.
Published: (2015-11-01)

OnabotulinumtoxinA versus IncobotulinumtoxinA in the treatment of patients with idiopathic or neurogenic detrusor overactivity: A prospective, randomized study
by: A.G. Giannantoni, et al.
Published: (2020-07-01)

Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-blind, Placebo-Controlled Study
by: Mandar Jog, et al.
Published: (2020-12-01)

OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays
by: David Rupp, et al.
Published: (2020-06-01)

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
by: Prager W, et al.
Published: (2013-04-01)

Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future.
by: Olivia Samotus, et al.
Published: (2016-01-01)

Botulinum Toxin Effects on Sensorimotor Integration in Focal Dystonias
by: Maria Ilenia De Bartolo, et al.
Published: (2020-04-01)

Botulinum Toxin Physiology in Focal Hand and Cranial Dystonia
by: Barbara Illowsky Karp
Published: (2012-11-01)

Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems
by: Kazerooni R, et al.
Published: (2021-06-01)

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study
by: Rappl T, et al.
Published: (2013-09-01)

Cannot write session to /tmp/vufind_sessions/sess_q27kcldjjbnu42p64i3i9hcl70